Meet our new member of Editorial Board: Prof. Tao Ren

Prof. Tao Ren works as the Director of Oncology Department, first affiliated hospital, Chengdu Medical College.

 

Prof. Ren received his Ph.D. in Oncology Science in the Third Military Medical University. Chongqing, China.

 

He studied in Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, Florida, USA as a Visiting Scholar in 2014-2015.

 

His main research interests focus on cancer pharmacology, anticancer drug chemotherapy, drug-resistance, APE1 and tumor.

 

His selected publications as first author:

Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.

 

Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of APE1-activated IL-6/STAT3 signaling pathway.

 

Welcome Prof. Tao Ren join our team!